COMPASS: COordinating care and iMproving outcomes in PAtients with pustular pSoriaSis

COMPASS: COordinating care and iMproving outcomes in PAtients with pustular pSoriaSis

Current Status
Not Enrolled
Get Started
This course is currently closed

Neutrophilic dermatoses are a group of heterogeneous disorders characterised by the infiltration of non-infectious neutrophils in the skin, with diverse cutaneous features (e.g., nodules, pustules, bulla, erosions, ulcerations) and extracutaneous symptoms.1 Common systemic findings such as fever, elevated inflammatory markers, inflammatory bowel disease and/or osteoarticular involvement suggest possible common pathogenic links (Figure 1).2 The mechanisms underlying neutrophilic dermatoses are not fully understood, but they may be viewed as a spectrum of autoinflammatory disorders, with several gene alterations identified and a central role for the interleukin-1 (IL-1) pathway.

Upon completion of this course, we expect that you would be able to compare and contrast the different neutrophilic dermatoses and phenotypes of pustular dermatoses to help you overcome challenges in diagnosing and managing this group of skin conditions.

Figure 1. Overlapping features of pustular dermatoses. (From Naik HB, Cowen EW. Dermatol Clin. 2013 Jul;31(3):405-25.)
CAMPS, CARD 14-mediated pustular psoriasis; DIRA, deficiency of IL-1 receptor antagonist; DITRA, deficiency of the IL-36 receptor antagonist; GPP, generalized pustular psoriasis; PAPA, pyogenic arthritis, pyoderma gangrenosum, and acne; PASH, pyoderma, acne and suppurative hidradenitis; PPP, palmoplantar pustulosis; SAPHO, synovitis, acne, pustulosis, hyperostosis and osteitis; SPD, subcorneal pustular dermatosis.2

References: 1. Salem I, Kimak M, Conic R, et al. Neutrophilic dermatoses and their implication in pathophysiology of asthma and other respiratory comorbidities: a narrative review. Biomed Res Int. 2019 Jun 10;2019:7315274. 2. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013 Jul;31(3):405-25.